Please login to the form below

Not currently logged in
Email:
Password:

Former Genzyme group vice president joins Vedanta Biosciences

Dr Bruce Roberts takes up the role of chief scientific officer

Vedanta Biosciences Dr Bruce RobertsVedanta Biosciences has appointed Dr Bruce Roberts as chief scientific officer at its new Cambridge, Massachusetts, site.

Dr Roberts will take responsibility for the company's research and development division, bringing over 30 years of experience in biotechnology and pharmaceutical drug discovery and development to the firm.

He first joined Sanofi Genzyme as general manager of its Cambridge, UK-based therapeutic antibody centre in 2004 before being promoted to group vice president and head of neuro-immunology and immune-mediated disease research in 2006.

In this role, Dr Roberts directed multiple clinical trials for the treatment of autoimmunity, cancer and multiple sclerosis as well as managing research efforts into a number of now-approved products.

Vedanta's chief executive officer Dr Bernat Olle said: “Bruce brings decades of drug development experience across a broad range of novel biologic drug modalities and a proven track record of driving the discovery and development of multiple approved drugs in immunology.

“His experience and leadership in pioneering new drug modalities will be invaluable as we advance our pipeline of microbiome-modulating therapies.”

Dr Roberts said: “Microbiome modulation is among the most exciting and rapidly evolving fields in science and it has tremendous potential to change the way medicine is practiced.

“I am excited to join one of the leading teams in this field and I look forward to driving Vedanta's technology platform and pipeline forward.”

29th March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Diagnosing the lag in neuropsychiatric treatments
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop...
CBC
Building Europe’s next breakthrough biotechs
Start Codon's Daniel Rooke on fostering biotech success in Cambridge, UK...
Tactful screening & participant sensitivity
Screening participants can involve asking personal questions that could be perceived as intrusive. Here CMR explores the implications of such lines of questioning....

Infographics